Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

This early-stage study tests an experimental drug called HDM2006 in about 48 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the right dose. Researchers will also look for early signs that th…

This study tests a new tablet called HDM1002 in 360 adults with type 2 diabetes whose blood sugar is not well controlled by diet and exercise alone. Participants will receive either the study drug or a placebo for 40 weeks to see if it safely lowers blood sugar levels. The goal i…

This early-phase study tests a new drug called HDM2017 in 96 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive the drug and are…

This study tests an experimental drug called HDM1005 in 240 adults with type 2 diabetes whose blood sugar is not well controlled by diet and exercise alone. Participants will receive either HDM1005 or a placebo for 36 weeks, then everyone gets the drug for another 16 weeks. The m…

This study tests whether a combination of three diabetes drugs (metformin, SGLT-2 inhibitor, and GLP-1 receptor agonist) works better than other oral medications for people with type 2 diabetes whose blood sugar is not well controlled. About 430 adults aged 18-75 with a BMI of 20…

This early-phase study tests a new drug called HDM2024 in about 63 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check if the drug is safe and to find the best dose. Participants receive the drug once every three weeks, an…

This early-stage study tests a new drug called HDP-101 in 15 Chinese patients with multiple myeloma, a type of blood cancer. The goal is to find a safe dose and see if the drug can shrink tumors. Participants must have tried other treatments first.

This study tests a new medicine called HDM1005, given as a weekly injection, to help Chinese adults with obesity or overweight lose weight. About 825 participants will receive either the drug or a placebo for 52 weeks, along with diet and exercise advice. The main goal is to see …

This study tests an experimental drug called HDM1005 to help obese adults who do not have diabetes lose weight. About 240 people will receive either the drug or a placebo injection. The main goal is to see how much weight they lose after 22 weeks, and whether the drug is safe.

This study tests a new drug called HDM1005 against an existing weight-loss medication, tirzepatide, in 372 adults with obesity but without diabetes. Participants receive weekly injections for 52 weeks, plus diet and exercise counseling. The main goal is to see how much weight is …

This study tests a new cream (MC2-01) against a standard gel and a placebo in 537 Chinese adults with plaque psoriasis. The goal is to see if the cream clears skin better after 8 weeks of daily use. Participants apply the cream at home and attend check-ups to track skin improveme…

This study looks at how a new drug called HDM1002 interacts with five common medicines (metformin, empagliflozin, midazolam, valsartan, and warfarin) in overweight or obese Chinese adults aged 18-45. About 111 healthy volunteers will take these drugs separately and together to me…